Literature DB >> 876954

Absorption, distribution and elimination of mexiletine.

L F Prescott, A Pottage, J A Clements.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 876954

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


× No keyword cloud information.
  36 in total

Review 1.  Therapeutic drug monitoring of antiarrhythmic drugs.

Authors:  Gesche Jürgens; Niels A Graudal; Jens P Kampmann
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

Review 2.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

Review 3.  Therapeutic drug monitoring: antiarrhythmic drugs.

Authors:  T J Campbell; K M Williams
Journal:  Br J Clin Pharmacol       Date:  1998-10       Impact factor: 4.335

Review 4.  Effects of cardiovascular disease on pharmacokinetics.

Authors:  V Rodighiero
Journal:  Cardiovasc Drugs Ther       Date:  1989-10       Impact factor: 3.727

5.  [Treatment with mexiletine. Clinical and pharmacokinetic studies].

Authors:  H Breithaupt; A Schmidt
Journal:  Klin Wochenschr       Date:  1988-06-01

6.  Evaluation of antagonism of aconitine-induced dysrhythmias in mice as a method of detecting and assessing antidysrhythmic activity.

Authors:  E Winslow
Journal:  Br J Pharmacol       Date:  1980       Impact factor: 8.739

7.  Effect of rifampicin treatment on the kinetics of mexiletine.

Authors:  P J Pentikäinen; I H Koivula; H A Hiltunen
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of the newer antiarrhythmic agents.

Authors:  A M Gillis; R E Kates
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

Review 9.  Mexiletine: a review of its pharmacological properties and therapeutic efficacy in arrhythmias.

Authors:  C Y Chew; J Collett; B N Singh
Journal:  Drugs       Date:  1979-03       Impact factor: 9.546

10.  The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.

Authors:  F Broly; N Vandamme; C Libersa; M Lhermitte
Journal:  Br J Clin Pharmacol       Date:  1991-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.